Background: The histologic grade of a prostate needle-core biopsy specimen can determine whether a patient with prostate cancer is a candidate for radical prostatectomy or other treatment. Incorrect histologic grading can result in inappropriate treatment and possible liability. Thus, we conducted this study to determine the histologic-grading accuracy of prostate cancer needle-core biopsy specimens. Methods: Fifty-two patients with localized prostate cancer treated with radical prostatectomy were included in the study. The overall correlation between Gleason scores for needle-biopsy and prostatectomy specimens was evaluated by analyzing the following parameters: biopsy-core number; accurate biopsy-core length; prostate volume; and preoperative, serum prostate-specific antigen (PSA) level. A "downgrade" was defined as the Gleason score for the prostatectomy specimen being greater than that for the biopsy specimen, whereas an "upgrade" was defined as the converse. Results: No difference in Gleason scores was noted for 31% of specimens, whereas a downgrade was noted for 40%, and an upgrade for 29%. The accuracy of Gleason scores for biopsy specimens taken by the sextant systemicbiopsy method increased when specimens were > 15 mm in length. No correlation was noted between difference in Gleason scores and biopsy-core number, prostate volume, and preoperative serum PSA level. Conclusion: The accuracy of Gleason scores determined by needle biopsy in patients with prostate cancer seems to be unreliable. Therefore, further evaluation of patients is necessary. No correlations were noted between biopsymeasured errors in Gleason score and biopsy number, prostate volume, or preoperative serum PSA level. [J Chin Med Assoc 2005;68(4):167-171] 
Introduction
Prostate cancer is the most commonly seen urologic malignancy, and the histologic grade of prostate tumors is an important determinant of disease prognosis and survival. 1, 2 Although numerous grading systems exist for the evaluation of prostate cancer, the Gleason grading system is the most widely accepted. 3 This system is based on the glandular pattern of prostate tumors, as identified at relatively low magnification.
Both the primary (predominant) and secondary (second most prevalent) architectural patterns are identified and assigned a score from 1-5, with 1 being the most differentiated and 5 the least differentiated. The Gleason scores of prostate biopsy specimens are used to predict the severity of prostate cancer, [4] [5] [6] and unless prostatectomy is performed, Gleason scores are determined from such specimens.
The management of patients with localized prostate cancer is based on clinical stage, serum prostate-specific antigen (PSA) level, and Gleason score of the prostate biopsy specimen. In patients with high Gleason-score prostate cancer, the likelihood of disease recurrence increases after radical prostatectomy. [4] [5] [6] In contrast, many investigators have suggested that patients with clinically localized, welldifferentiated or moderately differentiated prostate cancer are not at risk of death from cancer within 10-15 years of diagnosis. [7] [8] [9] Although the Gleason score of a prostate biopsy specimen dictates the clinical management of localized prostate cancer, King and Long 10 found that the accuracy of Gleason scores for prostate biopsy specimens was as low as 42%. To our knowledge, the measurement of such accuracy has never been reported in the Taiwanese literature. Therefore, we aimed to determine whether there was a correlation between the Gleason scores of biopsy specimens and the need for radical prostatectomy in patients with prostate cancer.
Methods

Study population
Between April 1996 and July 2002, retropubic radical prostatectomies were performed in 65 patients with clinically localized prostate cancer (stages cT1 and cT2) confirmed by transrectal ultrasound-guided biopsy of the prostate. Prostate cancer was diagnosed in 57 patients at the China Medical University Hospital, and in 8 patients at another institution, but all patients underwent surgery at the former institution. Patients' medical records and pathologic reports were reviewed. Twelve patients were excluded from the study for the following reasons: no detailed medical records (n = 9); the tumor volume of biopsy-core specimens was too small to grade (n = 2); and salvage prostatectomy had to be performed after biochemical progression after initially curative radiation therapy (n = 1).
Biopsy procedure and measurements
Systematic sextant biopsy, as described by Hodge et al, 11 was performed in our institution before October 2002 in 24 patients, and either the 10-core or 12-core biopsy technique (lateral and systematic sextant biopsy), as described by Presti et al, 12 was performed in 20 cases. An 18-gauge, automatic, spring-loaded, coretissue, biopsy needle (Bard ® Magnum ® , CR Bard Inc, Covington, GA, USA), with a 22-mm preset length was used for transrectal ultrasound-guided biopsy. The biopsy and prostatectomy specimens were reviewed by 1 staff pathologist, and tumor grade was determined according to the Gleason scoring system. 3 The overall correlation between Gleason scores for needle-biopsy and prostatectomy specimens was evaluated by comparing the biopsy-core number, accurate biopsy-core length, prostate volume, and preoperative serum PSA level with Gleason scores obtained from needle-biopsy and prostatectomy specimens. Biopsy-core length was measured after biopsy specimens had been fixed in 10% formalin. Prostate volume was measured before such fixation and was calculated by the prolate-ellipsoid volume formula. A "downgrade" was defined as the Gleason score for the tumor specimen from prostatectomy being greater than that for the biopsy specimen, whereas an "upgrade" was defined as the converse.
Statistical analyses
Values for biopsy-core number and accurate biopsycore length were compared by Fisher's exact test. Univariate analysis was used to determine the correlations of prostate volume and preoperative serum PSA level with differences in Gleason scores between needle-biopsy and prostatectomy specimens. A p value of less than 0.05 was considered statistically significant. All analyses were performed using SPSS version 9.0 (SPSS Inc, Chicago, IL, USA).
Results
Demographic data
Fifty-two patients were included in the study, although 8 of them had undergone prostate biopsy at another institution. Patient age ranged from 49-75 years (mean, 67 years). Preoperative serum PSA level ranged from 1.55-41.45 ng/mL (mean, 15.68 ng/mL), and prostate volume ranged from 16.75-94.24 mL (mean, 50.65 mL).
Gleason scores
Gleason scores ranged from 3-10 for biopsy-core specimens, and from 3-9 for radical prostatectomy specimens. The correlation between Gleason scores obtained from biopsy and prostatectomy specimens is shown in Table 1 . There were no differences in Gleason scores in 31% of specimens, but scores were downgraded in 40% of specimens, and upgraded in 29% (Table 2) .
Gleason-score differences were examined for possible correlation with the number of biopsy cores, length of biopsy core, prostate volume, and serum PSA level, among the 44 patients who underwent biopsy and prostatectomy at our hospital (Table 3) . In sextant systemic biopsy, the accuracy of biopsy- Gleason scores for 4 prostatectomy specimens were 3 units greater than corresponding scores for biopsy specimens taken from the same individuals (Table 4) . Preoperative serum PSA values ranged from 5.76-12.00 ng/mL (mean, 9.88 ng/mL), and prostate vol- 
Discussion
This study found that the accuracy of Gleason scores for needle-biopsy specimens of the prostate was only 31%. King and Long 10 pooled data from 10 studies (n = 2687) and found that such accuracy was 42% (range, 28-58%). They suggested that a methodology using more biopsy cores, combined with consensus in pathologic evaluation, could improve Gleason-score accuracy. However, Thickman et al 13 concluded that 6 biopsy cores were optimal for achieving maximum Gleason-score accuracy, and in the present study, more than 6 biopsy-core specimens did not increase such accuracy. Bostwick 14 reported that Gleason scores for prostate needle biopsy specimens taken with an 18-gauge needle from 316 patients were only 35% accurate. He did not find any correlation between the error in biopsy Gleason score and prostate volume, prostate weight, or preoperative serum PSA level. In our study, we also found that prostate volume, prostate weight and preoperative serum PSA levels were not linked to the accuracy of Gleason scores for needle-biopsy specimens.
Although all biopsy needles in this study were 18-gauge and had a set length of 22 mm, not all biopsy specimens were the same length. In specimens taken by sextant biopsy, the accuracy of Gleason scores increased when biopsy specimens were > 15 mm in length. However, this correlation was not evident in specimens taken by the 10-or 12-needle biopsy procedure. Ruijter et al 15 suggested that at least 6 biopsy specimens, each measuring 15 mm in length, should be obtained to minimize grading error. Some investigators have suggested that Gleason scores for samples taken with a 14-gauge biopsy needle are more accurate than scores for samples taken with an 18-gauge needle. [16] [17] [18] [19] However, other authors have reported that Gleason scores for samples taken with an 18-gauge needle are just as accurate as those for samples taken with a 14-gauge needle. 13, 14, 20 Adequate biopsy tissue for interpretation increases the accuracy of Gleason scores for needle-biopsy specimens.
Gleason scores for 4 specimens obtained by prostatectomy were 3 units greater than corresponding scores for biopsy specimens taken from the same individuals: 3 of the biopsy specimens had a Gleason score of 2 + 2, and 1 specimen had a score of 2 + 3. However, after analyzing specimens from all 52 patients, we found no correlation between the initial biopsy Gleason score and biopsy-core number, accurate biopsy-core length, prostate volume, or preoperative serum PSA level. One of the patients had a very large prostate (94.24 mL) and only underwent sextant biopsy. The other 3 patients underwent either 10-or 12-core biopsy, but the biopsy-core lengths were < 15 mm. The sampling error in these cases may have been due to grading error.
Although the histologic grade of needle-biopsy specimens is frequently used in clinical decisionmaking, the reliability of needle-biopsy Gleason score is low.
13,14,21,22 King 23 suggested that, given the clinical implications of Gleason scores, the staging of organconfined prostate cancer should include the likelihood of histologic upgrading when Gleason scores are used in the following settings: (1) stratification of patients for clinical trials; (2) comparison of results for specific therapies based on biopsy grading; (3) the use of "look-up" tables or formulae to predict risks for upgrading; and (4) the recommendation of radical therapy.
The accuracy of Gleason scores for needle-biopsy specimens in our study was 31%. No correlation between biopsy Gleason-score error and biopsy number, prostate volume, or preoperative serum PSA level was noted. In conclusion, adequate tissue in biopsy cores is important for accurate tumor grading, and treatment options for prostate cancer should not be based entirely on Gleason scores for needle-biopsy specimens.
